The impact of peripheral arterial disease on early outcome after transcatheter aortic valve implantation

Sinning, Jan‐Malte; Horack, Martin; Grube, Eberhard; Gerckens, Ulrich; Erbel, Raimund; Eggebrecht, Holger; Zahn, Ralf; Linke, Axel; Sievert, Horst; Figulla, Hans‐Reiner; Kück, Karl‐Heinz; Hauptmann, Karl Eugen; Hoffmann, Ellen; Hambrecht, Rainer; Richardt, Gert; Sack, Stefan; Senges, Jochen; Nickenig, Georg; Werner, Nikos

doi:10.1016/j.ahj.2012.04.016

Cited by 68 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 60.8% (n ¼ 5,392) of patients, an Edwards SAPIEN or SAPIEN XT balloon-expandable valve (both Edwards Lifesciences, Irvine, California) was implanted, and in 21.4% (n ¼ 1,899) of patients, the self-expandable third-generation Medtronic CoreValve (Medtronic Inc., Minneapolis, Minnesota) prostheses were used, whereas 3 studies (comprising 15.8% of patients, n ¼ 1,583) did not specify the type of valve implanted. 20,22,23 Because of the infrequent reporting of conversion to surgery and intraprocedural death, no reliable incidence could be reported for these events. Table 2 summarizes procedural TAVI characteristics in the various studies.…”

Section: Resultsmentioning

confidence: 99%

Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation

Giordana

D’Ascenzo

Nijhoff

et al. 2014

The American Journal of Cardiology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation

Giordana

D’Ascenzo

Nijhoff

et al. 2014

The American Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…The prospective, multicentre German TAVI Registry was initiated in 2009 to evaluate indication, intervention and clinical outcome and assess quality of life after TAVI in routine clinical practice 13 19 20. This registry, independently run apart from industry, is driven by the scientific interest of the participating centres and organised by the Institut für Herzinfarktforschung (IHF), Ludwigshafen, Germany.…”

Section: German Tavi Registrymentioning

confidence: 99%

“…Not surprisingly, major vascular complications are associated with an adverse outcome after TAVI,17 and interestingly, have also been noted to occur in patients undergoing TAVI via transapical access 11. This might be explained by the high prevalence of concomitant PAD in transapical TAVI patients, since PAD itself is an independent predictor of mortality after TAVI 11 19. Therefore, assessment of PAD, which is often associated with vascular complications, should play a crucial role in the pre-interventional selection process, regardless of the access site 19.…”

Section: The Evolution Of Tavimentioning

confidence: 99%

Transcatheter aortic valve implantation: the evidence

Sinning

Werner

Nickenig

et al. 2012

Heart

Self Cite

View full text Add to dashboard Cite

Transcatheter aortic valve implantation (TAVI) is the new standard-of-care for inoperable patients with better outcome than conservative management, including balloon valvuloplasty only. In high-risk patients, TAVI has clearly shown non-inferiority compared with surgical aortic valve replacement. Although data from national multicentre registries are very encouraging and we are already speculating about the use of TAVI in intermediate-risk patients, it is of note that the two commercially available and used transcatheter heart valves (THVs) have not yet been assessed by randomised clinical trials in those patients. Technological advances promise to simplify TAVI and to improve outcome by reducing the rate of TAVI-specific issues such as stroke, peri-prosthetic aortic regurgitation, acute kidney injury, vascular complications and conduction disturbances. Therefore, results from ongoing trials with the available THVs are urgently awaited. In future trials, screening, treatment and follow-up of TAVI patients will need to follow a standardised protocol to achieve better comparability of study data to address, decisively, the question of whether intermediate-risk or low-risk patients may also profit from a less invasive TAVI approach.

show abstract

“…Peripheral artery disease in our analysis was defined as any known history of peripheral angioplasty or surgery, presence of claudication, an ankle-brachial index of <0.9, and stenosis of the iliofemoral axis >50%. 13 After evaluation, all patients were discussed within the local interdisciplinary heart team. In this analysis, we excluded patients undergoing primary surgical cut down for vessel access and patients undergoing access-site closure with the use of investigational devices.…”

Section: Patient Populationmentioning

confidence: 99%

Routine Endovascular Treatment With a Stent Graft for Access-Site and Access-Related Vascular Injury in Transfemoral Transcatheter Aortic Valve Implantation

Sedaghat

Neumann

Schahab

et al. 2016

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

Background-Access-site and access-related vascular injury (ASARVI) is still a major limiting factor in transcatheter aortic valve implantation and affects the outcome of patients. Management strategies for ASARVI include manual compression, stent grafts, and vascular surgery. We hypothesized that the standard use of a self-expanding stent graft for the management of ASARVI is feasible and safe. Methods and Results-Of 407 patients treated by transfemoral transcatheter aortic valve implantation, 110 experienced ASARVI (27.0%). Of these, 96 (87.3%) were managed by the implantation of a self-expanding nitinol stent graft. In the majority of patients, minor vascular complications triggered the implantation of a stent graft (86.5%), mainly because of bleeding (90.6%) and dissection (5.2%) of the common femoral artery with high rates of primary treatment success (97.9%

show abstract

The impact of peripheral arterial disease on early outcome after transcatheter aortic valve implantation

Cited by 68 publications

References 25 publications

Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation

Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation

Transcatheter aortic valve implantation: the evidence

Routine Endovascular Treatment With a Stent Graft for Access-Site and Access-Related Vascular Injury in Transfemoral Transcatheter Aortic Valve Implantation

Contact Info

Product

Resources

About